HSV-2 vaccine shows significant clinical symptoms and viral shedding reductions at six months

Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose. Genocea, a company pioneering novel T cell vaccines and immunotherapies, reported the results from the ongoing trial of GEN-003 today as an oral presentation at the World Vaccine Congress, being held March 24-26 in Washington, DC.

The ongoing Phase 1/2a double-blind, placebo-controlled study showed that patients treated with GEN-003 at the 30 microgram dose level experienced a 72 percent reduction in lesion days six months after study initiation compared to baseline levels (p<0.001). The results expand upon the positive initial data reported as a late breaker at ICAAC in September 2013 showing that patients treated at the 30 microgram dose level experienced a 50 percent reduction in mean viral shedding from baseline (p<0.001) immediately following three doses, which was maintained at six months (p<0.001). Treatment with GEN-003 was well tolerated overall.

"HSV-2 is an incurable sexually transmitted disease that affects over 500 million people worldwide, and current oral drugs require costly, inconvenient daily dosing to optimally control the painful symptoms of HSV-2 outbreak or to block viral transmission to other individuals," said Jessica Baker Flechtner, PhD, Genocea senior vice president of research, who presented the data. "This is the first time an HSV-2 immunotherapy has shown a significant impact on clinical symptoms, and the fact that GEN-003 has shown durable results six months after study initiation is very encouraging. Results of this initial clinical study of GEN-003, if confirmed by further clinical testing, suggest a compelling best-in-class profile for this therapeutic against HSV-2 infection, that may lead to reductions in both disease transmission and recurrent disease outbreaks."

"These exciting results support the ability of GEN-003 to provide a durable reduction in clinical symptoms, and validate the ATLAS™ platform as a tool for the rational discovery and development of novel vaccines and immunotherapies," said Chip Clark, president and chief executive officer of Genocea. "We expect to announce twelve-month data from this study in mid-2014, and also plan to initiate additional Phase 2 testing of GEN-003 in 2014 to further optimize dosing."

Provided by Genocea Biosciences, Inc.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Novel vaccine reduces shedding of genital herpes virus

Sep 12, 2013

Sexually transmitted infection researchers potentially have reached a milestone in vaccine treatment for genital herpes, according to a report to be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy ...

NIH launches trial of investigational genital herpes vaccine

Nov 08, 2013

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

Research shows progress toward a genital herpes vaccine

Jan 04, 2012

An investigational vaccine protected some women against infection from one of the two types of herpes simplex viruses that cause genital herpes, according to findings in the New England Journal of Medicine.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments